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Clinical Value of Ezrin Expression in Primary
Osteosarcoma
I n t r o d u c t i o n
Primary osteosarcoma is the most common primary bone tumor
that predominantly develops in adolescents and young adults. Even
after the introduction of aggressive perioperative chemotherapy and
wide excision of tumors, a substantial number of patients still
experience local recurrence or distant metastases after curative
resection of their primary tumors. The clinical outcome is extremely
poor for these recurrent or metastatic patients (1). Thus, several
attempts have been made to identify the prognostic factors for
survival for the patients with osteosarcoma and to identify the
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Purpose
Ezrin is a membrane cytoskeletal linker protein and it is known to be associated with
metastasis of primary osteosarcoma. The aim of this study is to determine the relationship
between an ezrin expression and several key clinical parameters and to elucidate its
potential prognostic value for patients with osteosarcoma. 
Materials and Methods
Seventy patients with histologically confirmed osteosarcoma and who had no distant
metastasis were enrolled between 1995 and 2005 at Yonsei Cancer Center, Severance
Hospital, Korea. The clinical parameters were retrospectively reviewed and immunohistoche-
mical staining (IHC) for ezrin was performed using the surgically resected specimens.
Results
Of the 70 tumor specimens, 39 (55.7%) revealed an ezrin expression. More of an osteoblastic
histology and an elevated initial ALP level were observed in the ezrin positive patients than in
the ezrin negative patients (p=0.008 and 0.001, respectively). The proportion of patients who
favorably responded to neoadjuvant chemotherapy (≥90% necrosis) was significantly
higher in the group of ezrin positive patients than that in the group of ezrin negative patient
(72.2% vs 45.2%, respectively, p=0.024). The ezrin positive patients showed more frequent
recurrence than did the ezrin negative patients (64.1% vs 35.5%, respectively, p=0.017). The
patients with an ezrin expression also demonstrated poorer survival than did those patients
without ezrin expression (5-year EFS: 31.7% vs 61.3%, respectively, p=0.023, 5-year OS: 53.4%
vs 71.0%, respectively, p=0.022). When comparing EFS according to both an ezrin expression
and chemoresponsiveness, there were trends that the ezrin negative/chemoresponsive
group showed the best 5-year EFS (71.4%), followed by the ezrin negative/chemoresistant
group (52.9%), the ezrin positive/chemoresponsive group (38.1%) and the ezrin
positive/chemoresistant group (13.6%). These trends were statistically significant (p=0.036).
Conclusion
The expression of ezrin by IHC staining was found in 55.7% of the patients with metastasis-
free osteosarcoma. Immunoreactivity to ezrin is a negative prognostic factor for survival for
the patients suffering with osteosarcoma. Identifying an ezrin expression might offer a
valuable piece of information when treating patients with primary osteosarcoma. 
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patients with a high risk of developing recurrence from those
patients with a low risk (2,3). There are currently very limited
prognostic indicators; these include factors such as age, the tumor
site, the histologic type, the tumor volume and an elevated serum
alkaline phosphatase (ALP) level (4). 
Ezrin is a membrane cytoskeletal linker protein which is produced
by the expression of the Vil2 gene and ezin is a member of the ERM
(Ezrin-Radixin-Moesin) family (5,6). Ezrin is involved in the
interaction between cells or between cell and the extracellular
matrix. It is related to the Rho mediated signal transduction pathway
and to the Akt mediated apoptotic pathway. Ezrin is currently
known to play an important role in the metastasis of various human
cancers, including breast cancer, colorectal carcinoma, soft tissue
sarcoma and serous ovarian carcinoma (7-10). Furthermore, ezrin
has been suggested to be an importantly involved molecule in the
metastasis of human osteosarcoma. In a previous pilot study, a high
expression of ezrin was found to be associated with the early
development of metastases in a mouse model (11). In addition, it has
been noted that the disease-free interval is significantly shorter in
pediatric patients with a high ezrin expression (11). However, there
have been only a few reports regarding the expression of ezrin in
osteosarcoma or its relationship with other clinicopathologic
parameters (8,12,13). 
The aim of this study is to determine the relationship between an
ezrin expression and several key clinicopathologic features and to
elucidate the potential value of an ezin expression for predicting the
clinical outcome of patients with primary osteosarcoma. 
M a t e r i a l s  a n d  M e t h o d s
1 The patients and tumor samples
Seventy patients who were histologically confirmed as having
osteosarcoma and who had no clinical evidence of distant metastasis
at the time of diagnosis were enrolled between 1995 and 2005 at
Yonsei Cancer Center, Severance Hospital, Korea. All the patients
underwent neoadjuvant chemotherapy and wide resection of tumor. 
The clinicopathologic variables such as gender, age, the site of
osteosarcoma, the histologic type, the initial serum ALP level, the
type of surgery and the status of the resection margin were
retrospectively reviewed on the basis of the medical records. 
2 Immunohistochemistry 
Immunohistochemical (IHC) staining was performed on the
formalin-fixed, paraffin-embedded surgical specimens from all the
patients. The slides of 70 primary surgical specimens were
deparaffinized, rehydrated and then processed using the labeled
streptavidin-biotin-peroxidase method. Antigen retrieval was
performed by heating the slides in 10 mmol/L sodium citrate buffer
(pH 6.0) for 15 minutes at 95℃. The slides were then incubated in
10% normal blocking serum for 30 minutes. After that, they were
incubated overnight at 4℃ in appropriately diluted mouse
monoclonal antibody that was reactive to ezrin (1 : 300;
NeoMarkers, Fremont, CA). After washing with Tris buffer, the
tissue slides were incubated with biotin-labelled secondary
antibodies and then the slides were reacted with streptavidin-
horseradish peroxidase with using the DAKO LSAB kit (DAKO,
Glostrup, Denmark) at room temperature for 30 minutes at each
step. Nova red (Vector Laboratory, Burlingame, CA) was used as
the chromogen and hematoxylin was used as the nuclear
counterstain. The ezrin expression was graded as negative (＜10%
of the cells stained), 1+ (10�33% of the cells stained), 2+ (34�
67% of the cells stained), and 3+ (68�100% of the cells stained).
Table 1. Baseline clinical characteristics
Variables N %
Sex Male 37 52.9
Female 33 47.1
Age at diagnosis 15.7 (3.8�64.4)
Site Femur 46 65.7
Tibia 9 12.9
Fibula 2 2.9
Humerus 11 15.7
Others 2 2.9
Histology Osteoblastic 36 51.4
Chondroblastic 12 17.1
Fibroblastic 3 4.3
Mixed 16 22.9
Others 3 4.3
Initial ALP Normal 14 20.0
Elevated 53 75.7
N/A* 3 4.3
Surgery type Amputation 7 10.0
Limb salvage 62 88.6
Others 1 1.4
Chemotherapy response ＜90% necrosis 27 38.6
≥90% necrosis 40 57.1
N/A 3 4.3
Resection margin Adequate 65 92.9
Inadequate 4 5.7
N/A 1 1.4
Recurrence No 34 48.6
Yes 36 51.4
Lung metastasis No 40 57.1
Yes 30 42.9
*not available.
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3 Statistical analysis
For survival analysis, overall survival (OS) was defined as the
time interval between the date of surgery to the date of death or the
last follow-up. Event-free survival (EFS) was defined as the time
interval from surgery to progressive disease, death from any cause
other than progression, or a second primary cancer.
The Statistical Package for Social Sciences (SPSS) version 12.0
for Windows (SPSS, Inc., Chicago, IL) was used for the statistical
analysis. The correlation between the clinicopathologic variables
and the ezrin expression was analyzed using independent sample t-
tests for the continuous variables and the chi-square test for the
discrete variables. Survival curves were calculated using the
Kaplan-Meier method, and comparisons between the different
groups were analyzed using the log-rank test. A multivariate
analysis was done by Cox’s regression to identify the prognostic
factors for EFS and OS from the variables that proved significance
on the univariate analysis. The accepted level of statistical
significance was p＜0.05.
R e s u l t s
Table 1 shows the baseline clinical characteristics. The male-to-
female ratio was 1.12. The median age at the time of diagnosis of
osteosarcoma was 15.7 years (range: 3.8�64.4 years). The most
prevalent primary site of osteosarcoma was the femur (65.7%) and
the most common histologic subtype was osteoblastic osteosarcoma
(51.4%). Most patients (88.6%) underwent a limb salvage operation
and the surgical specimens revealed favorable responses (≥90%
necrosis) in 40 patients (57.1%).
Of the 70 tumor specimens, 39 (55.7%) revealed the expression
of ezrin, while 31 (44.3%) showed no expression of ezrin. Fig. 1
Ezin 2+ Ezin 3+
Negative Ezin 1+
Fig. 1. Examples of ezrin immunoreactivity in osteosarcoma. Original magnification×200.
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shows the representative expressions of ezrin based on the staining
intensities. In the positive cases, ezrin was expressed in the
cytoplasm of the osteosarcoma tumor cells.
With the median follow-up of 59.9 months, among the 70
enrolled patients, 32 patients (45.7%) remained event-free, while 36
patients (51.4%) had recurrent disease and 2 patients (2.9%) died of
postoperative infectious complications without any evidence of
recurrence. Of the 36 recurred patients, 29 died of progressive
disease and 8 survived until the time of analysis. After the curative
resection of tumor, 68 patients underwent adjuvant chemotherapy,
while the remaining 2 died of postoperative complications.
Table 2 shows the clinicopathologic parameters according to the
expression of ezrin. There were no differences in gender, age, the
site of tumor, the type of surgery and the status of the resection
margin between the patients with or without an expression of ezrin.
However, a more prevalent osteoblastic histology and a more
elevated initial ALP level were observed in the ezrin positive
patients than in the ezrin negative patients (p=0.008 and 0.001,
respectively). The proportion of patients who favorably responded
to neoadjuvant chemotherapy (≥90% necrosis) was significantly
higher for the ezrin positive patients than that of the ezrin negative
patient (72.2% vs 45.2%, respectively, p=0.024). In addition, the
patients with ezrin positivity showed more frequent tumor
recurrence than did those patients with ezrin negativity (64.1% vs
35.5%, respectively, p=0.017).
The 5-year OS was 61.1% and the 5-year EFS was 45.2% for all
the patients. A poor histologic response to previous chemotherapy
(＜90% necrosis) and an expression of ezrin were negative
prognostic factors on the univariate analysis (p=0.047 and 0.022,
respectively), while gender, the tumor site, the histologic type, the
initial ALP level, the type of surgery and the resection margin had
no prognostic value (Table 3) (Fig. 2). On the Cox regression
multivariate analysis, an ezrin expression showed independent
significance for EFS (p=0.025), whereas its significance was
marginal for OS (p=0.055) (Table 4). 
D i s c u s s i o n
Osteosarcoma is a very heterogenous disease entity and there are
multiple factors that have an influence on the prognosis of
osteosarcoma. Some patients have shown a good response to
neoadjuvant chemotherapy and they were eventually cured by the
subsequent surgery, while others have shown resistance to
Ezrin (-) (n=31) Ezrin (+) (n=39)
N % N %
p-value
Sex Male 19 61.3 18 46.2 0.208
Female 12 38.7 21 53.8
Age at diagnosis 15.5 (8.4�28.1) 16.0 (3.8�64.4) 0.310
Site Femur 18 58.1 28 71.8 0.477
Tibia 5 16.1 4 10.3
Fibula 2 6.5 0 0
Humerus 5 16.1 6 15.4
Others 1 3.2 1 2.6
Histology Osteoblastic 9 29.0 27 69.2 0.008
Chondroblastic 6 19.4 6 15.4
Fibroblastic 3 9.7 0 0
Mixed 11 35.5 5 12.8
Others 2 6.5 1 2.6
Initial ALP Normal 12 40.0 2 5.4 0.001
Elevated 18 60.0 35 94.6
Surgery type Amputation 5 16.1 2 5.1 0.220
Limb salvage 26 83.9 36 92.3
Others 0 0 1 2.6
Chemotherapy response ＜90% necrosis 17 54.8 10 27.8 0.024
≥90% necrosis 14 45.2 26 72.2
Resection margin Adequate 31 100.0 34 89.5 0.063
Inadequate 0 0 4 10.5
Recurrence No 20 64.5 14 35.9 0.017
Yes 11 35.5 25 64.1
Table 2.  Key clinical parameters according to ezrin expression 
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chemotherapy and the disease rapidly progressed (14). The well
known clinical prognostic factors are age, the tumor site, the
histologic type, the tumor volume and an elevated serum alkaline
phosphatase (ALP) level. Yet the molecular biomarkers of
osteosarcoma are not well known and much remains to be
investigated. There have been several reports on the expression
patterns of molecular markers such as VEGF, ErbB-2, P-
glycoprotein and ezrin, and their prognostic value for osteosarcoma
Variables N 5-year EFS (%) p-value 5-year OS (%) p-value
Sex Male 37 37.8 0.116 48.2 0.153
Female 33 54.2 75.6
Site Femur 46 45.2 0.340 63.0 0.376
Tibia 9 55.6 62.2
Fibula 2 50.0 50.0
Humerus 11 45.5 63.6
Others 2 0.0 0.0
Histology Osteoblastic 36 38.2 0.160 52.8 0.108
Chondroblastic 12 58.3 75.0
Fibroblastic 3 100.0 100.0
Mixed 16 37.5 62.5
Others 3 66.7 66.7
Initial ALP Normal 14 64.3 0.130 64.3 0.510
Elevated 53 39.3 58.0
N/A* 3
Surgery type Amputation 7 71.4 0.210 85.7 0.133
Limb salvage 62 43.0 59.3
Others 1
Chemotherapy response ＜90% necrosis 27 40.4 0.041 50.8 0.047
≥90% necrosis 40 50.0 62.3
N/A 3
Resection margin Adequate 65 47.1 0.226 64.3 0.068
Inadequate 4 25.0 25.0
N/A 1
Ezrin expression No 31 61.3 0.023 71.0 0.022
Yes 39 31.7 53.4
Table 3.  5-year survival rate according to clinicopathologic variables
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Fig. 2. Kaplan-Meier estimates of EFS and OS.
*not available.
Chan Kim, et al_Clinical Value of an Ezrin Expression in Osteosarcoma
VOLUME 41  NUMBER 3  SEPTEMBER   2009  143
(4). In this current study, ezrin was selected for IHC staining
because ezrin is known to be involved in the early processes of
metastasis and recurrence of osteosarcoma (11-13).
In our study, 55.7% of the osteosarcoma patients showed an
expression of ezrin. This result was consistent with the results of
previous reports that ranged from 40% to 60% (12,15,16). The
patients with an ezrin expression also experienced a greater
frequency of osteosarcoma recurrence after curative resection, and
they subsequently had poorer EFS and OS than did those patients
without an ezrin expression. The median EFS was 34.6 months for
the patients with an ezrin expression, while the EFS curve did not
reach the median for the patients without an ezrin expression
because more than half of the patients without an ezrin expression
survived. This negative prognostic value of an ezrin expression is
similar with the reports on other solid malignancies (8,9,17).
In the three major previous studies regarding the relationship
between the subtype of osteosarcoma and survival, the fibroblastic
subtype and the chondroblastic subtype showed better survival than
did the conventional osteoblastic subtype (18-20), but no
satisfactory explanation was given about this difference in the
prognosis. The present study demonstrated that the conventional
osteoblastic histology is associated with a frequent expression of
ezrin, as 27 out of 36 (75%) patients with an osteoblastic histology
expressed ezrin according to IHC staining, while only 6 of 12 (50%)
of the patients with an chondroblastic subtype showed a ezrin
expression and none of the patients with a fibroblastic subtype
showed an ezrin expression. Because our study’s sample size was
small, we cannot conclude a definite relationship between the
histologic subtype and an ezrin expression. Yet we suggest the
possibility that the more frequent ezrin expression in the osteoblastic
subtype might be related to a bad prognosis for the osteoblastic
subtype. An ezrin expression and more aggressive features for
metastasis could be associated with a bad prognosis for this subtype.
The concept of neoadjuvant chemotherapy was introduced in the
late 1970s and this is now accepted as one of standard treatments for
metastasis-free osteosarcoma (21,22). The advantages of neoadjuvant
chemotherapy are the early treatment of potentially undetectable
micrometastasis and the opportunity to assess the histologic
response to neoadjuvant chemotherapy. Although the patients in the
previously reported studies that responded favorably to neoadjuvant
chemotherapy with ≥90% necrosis had a 70�87% 5-year OS, the
patients with a poor response of ＜90% necrosis had less than
50.0% 5-year OS (2,22,23). However, the response to neoadjuvant
chemotherapy is not always a good prognostic factor. A substantial
number of good responders still had early recurrence at distant sites
after curative resection. In this current study, among the 40 good
responders, 10 patients (25.0%) recurred within 1 year after curative
resection, and 8 of whom revealed ezrin immunoreactivity in the
surgical specimen. In contrast, 10 of the 27 (37.0%) poor responders
were able to achieve long term survival of more than 5 years after
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Fig. 3. EFS and OS according to ezrin expression and chemoresponsiveness.
Table 4.  Cox’s multivariate model for survival
EFS OS
Variables
Relative risk 95% CI p-value Relative risk 95% CI p-value
Ezrin expression No 1 1
Yes 2.28 1.11�4.70 0.025 2.24 0.98�5.12 0.055
Chemotherapy response ＜90% necrosis 1 1
≥90% necrosis 0.57 0.29�1.11 0.101 0.86 0.40�1.88 0.711
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the surgery. Only 1 of these 10 long-term surviving poor responders
showed ezrin immunoreactivity in their surgical specimen. The EFS
curves, according to an ezrin expression and chemoresponsiveness,
showed similar trends, which is consistent with these result (Fig. 3).
The ezrin negative/ chemoresponsive group showed the best 5-year
EFS (71.4%), followed by the ezrin negative/chemoresistant group
(52.9%), the ezrin positive/chemoresponsive group (38.1%) and the
ezrin positive/chemoresistant group (13.6%) (p=0.036). Overall
survival according to an ezrin expression and chemoresponsiveness
also showed similar trends, but it was not significant (p=0.126). That is
to say, good responders with an ezrin expression might have a poorer
outcome with early metastasis than the poor responders without an
ezrin expression. Therefore, the good responders with an ezrin
expression, who were more likely to recur early in spite of a favorable
chemotherapy response, need more active tumor surveillance. Because
lung and bone were the most prevalent sites of distant metastasis of
osteosarcoma after the curative surgery (Table 5), regular follow-ups
that include imaging of the lungs and bones could be helpful for the
early detection of recurrence in this subset of patients.
C o n c l u s i o n
The expression of ezrin by IHC staining was found in more than
half (55.7%) of the patients with metastasis-free osteosarcoma.
Immunoreactivity to ezrin is a negative prognostic factor for OS and
EFS. Identifying an ezrin expression might offer a valuable piece of
information when treating patients with primary osteosarcoma. 
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R e f e r e n c e s
Ezrin (-) Ezrin (+) Total
Lung 6 (54.5%) 15 (60.0%) 21 (58.3%)
Bone 2 (18.2%) 2 (8.0%) 4 (11.1%)
Both lung and bone 2 (18.2%) 7 (28.0%) 9 (25.0%)
Others 1 (9.1%) 1 (4.0%) 2 (5.6%)
Table 5. Common sites of metastasis according to ezrin expression
